Status:
ENROLLING_BY_INVITATION
Histiocytosis in Injecting Drug Users
Lead Sponsor:
Tampere University Hospital
Collaborating Sponsors:
Tampere University
University of Oulu
Conditions:
Histiocytosis
Eligibility:
All Genders
18-70 years
Brief Summary
The goal of this observational study is to describe a new disease condition of histiocytosis related to injecting drug use, its preconditions, symptoms, signs, findings, and prognosis in a detailed an...
Detailed Description
Comprehensive patient data (disease history, findings, complications, laboratory findings, histopathology, and imaging) will be obtained from patient records of a single university hospital. Coded his...
Eligibility Criteria
Inclusion
- All identified adult patients in our records with a history of injecting drug use by dissolving tablets containing polyvinylpyrrolidone and (suspected) PVP-histiocytosis
Exclusion
- Other histiocytosis diagnosed by tissue samples and clinical information
Key Trial Info
Start Date :
May 29 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2030
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06573671
Start Date
May 29 2023
End Date
December 31 2030
Last Update
September 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tampere University Hospital
Tampere, Pirkanmaa, Finland, 33101